$XBI $72.60 | +4.94%
Table of Contents:
Covid Updates
#NVAX 0.0% (+22% AH) Novavax Statement on Stock Trading Halt; FDA Advisory Committee to Review Novavax’ COVID-19 Vaccine.
#NVAX 0.0% (+22% AH) FDA Advisory Committee Recommends Emergency Use Authorization of Novavax COVID-19 Vaccine for People Aged 18 Years and Older
#VERU +16.8% Veru Submits Emergency Use Authorization (EUA) Application to U.S. FDA for Sabizabulin, its Novel, Oral Antiviral and Anti-Inflammatory Drug Candidate for Hospitalized COVID-19 Patients at High Risk for ARDS
Pipeline Updates
#DBVT -1.9% (+29.4% AH) DBV Technologies Announces Positive Topline Results from Phase 3 EPITOPE Trial of Viaskin Peanut in Peanut-Allergic Toddlers
#MCRB +28.8% Seres Therapeutics Announces Confirmatory Results from Investigational Microbiome Therapeutic SER-109 ECOSPOR IV Open-Label Study in Recurrent C. Difficile Infection.
#ANNX +24.9% Annexon Biosciences Reports Phase 2 Clinical Trial Results Demonstrating Upstream Classical Complement Inhibition Associated with Clinical Benefit in Huntington’s Disease.
#BLUE +21.2% bluebird bio Announces Posting of Briefing Documents for Upcoming FDA Advisory Committee Meeting.
#ALDX +12.2% Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from the Phase 3 TRANQUILITY-2 Trial in Dry Eye Disease
#CVM +9.1% CEL-SCI Presents Phase 3 Multikine Head & Neck Cancer Data at ASCO
#CNCE +6.1% Phase 2 Dose‑Ranging Clinical Trial Results of CTP‑543 in Patients with Alopecia Areata published in the Journal of the American Academy of Dermatology.
#APLS +4.6% Apellis and Sobi Announce First Patient Dosed in Phase 3 VALIANT Study of Pegcetacoplan for IC-MPGN and C3G, Rare Kidney Diseases with High Unmet Medical Need.
#ASND +4.6% Ascendis Pharma A/S Announces Two Oral Presentations Highlighting the Potential for TransConâ„¢ PTH to be a Replacement Therapy for Adult Hypoparathyroidism at ENDO 2022.
#MRNA +3.8% Moderna Announces First Participants Dosed in Phase 3 Study of Seasonal Influenza Vaccine Candidate (mRNA-1010).
#BCRX +3.7% BioCryst Announces Approval of ORLADEYO® (berotralstat) by Swissmedic.
#JAZZ +3.6% Jazz Pharmaceuticals Presents Positive Data from Phase 2/3 Trial of Rylaze® (asparaginase erwinia chrysanthemi (recombinant)-rywn) in Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma at the ASCO 2022 Annual Meeting.
#HALO +3.5% Halozyme Announces Commercial Launch of TLANDOâ„¢, an Oral Treatment for Testosterone Replacement Therapy.
#ALVR +3.1% AlloVir Reports Blinded, Preliminary, Phase 2 Data Supporting the Ongoing Study of Posoleucel, a Multi-Virus-Specific T Cell Therapy, for the Treatment of BK Viremia in Kidney Transplant Recipients.
#TALS +0.1% Talaris Therapeutics Presents Additional Phase 2 Data and Analyses at American Transplant Congress 2022
#ASLN -2.4% ASLAN Pharmaceuticals Initiates Scientific Collaboration to Investigate the Distinct Role of IL-13 Receptor Signaling in Atopic Dermatitis.
#PMVP -21.7% PMV Pharmaceuticals Initial PC14586 Phase 1 Data Presented at ASCO Demonstrated Anti-Tumor Activity Across Multiple Solid Tumor Types With a p53 Y220C Mutation
Want to get weekly catalyst updates?
*We never spam you - unsubscribe anytime*
Business Updates
#EIGR -0.8% Eiger BioPharmaceuticals Enters into $75M Term Loan Agreement and $5M Stock Purchase Agreement with Innovatus Capital Partners to Refinance Existing Debt Facility and Further Strengthen Cash Position Ahead of Key Milestones
Posted by FS/JM